ACAD vs ZBH
ACADIA Pharmaceuticals Inc. vs Zimmer Biomet — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
VS
| Metric | ACAD | ZBH |
|---|
| AI Score |
69
|
69
|
| Price |
$29.41
|
$97.22
|
| P/E Ratio |
13.07×
|
23.54×
|
| ROE |
31.9%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
69.9%
|
| Debt / Equity |
0.06×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
78.4
|
63.1
|
| Beta |
0.845
|
0.462
|
| Expected Upside |
—
|
+3.7%
|
AI Committee View
Current Innellis committee reasoning for ACAD versus ZBH.
The committee scores are tied.
ACAD and ZBH both score 69/100.
ACAD Committee View
83% agreement
6 analysts
The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 13.2 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- RSI at 78 is in overbought territory — Technical
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.3% signals elevated volatility — Risk
ZBH Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical